Our CEO, Christer Nordstedt, will together with CSO Olof Larsson present some novel developments related to the TRPV1 platform. Apart from a scientific and medical update of the platform, Johan Olsson from Biostratiq Advisor Transactions has been asked to present their external valuation of the TRPV1 programme.
